Open company graph database — free web & API
Login

Sanofi Inc.

サノフィ株式会社Sanofi K.K.Alias
Ticker
—
Listed market
—
Country
Japan
Employees (consolidated)
1,300
Related companies
4
§01

Basic information

BASIC
Head office
Tokyo Opera City Tower, 20-2 Nishi-Shinjuku 3-chome, Shinjuku-ku, Tokyo 163-1488Sources
Chief executive
Sources
Capital
500,000,000  (5 100 million)
Employees (non-consolidated)
1,300 people
Employees (consolidated)
1,300 people
Start date
End date
§02

Websites

1 DOMAINS
§03

Business

2
Manufacturing, sales, and import of pharmaceuticals and related products, and research and developmentSourcesProvision of medical pharmaceuticals and vaccinesSources
§04

Related companies

4 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
SS Pharmaceutical Co., Ltd. Sources
Group Subsidiary
サノフィ・パストゥール株式会社 Sources
Group Subsidiary
ジェンザイム・ジャパン株式会社 Sources
Group Subsidiary
バイオベラティブ・ジャパン株式会社 Sources
Group Subsidiary
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

7 EVENTS

Established Sanofi Aventis Inc. through the merger of Sanofi Sante Labs Inc. and Aventis Pharma Inc.Sources

Changed company name to "Sanofi Inc."Sources

Absorbed Sanofi Pasteur Inc.Sources

Absorbed Zenzyme Japan Inc.Sources

Made SS Pharmaceutical Inc. a subsidiary through a business exchange with Merial Japan Inc.Sources

Integrated Bioverativ Japan Inc.Sources

Spun off SS Pharmaceutical Inc.Sources

§07

News

10 ARTICLES

Disaster Support for the Kumamoto EarthquakeSources

On November 5, 2026, we announced support for the disaster caused by the Kumamoto earthquake in Reiwa 8.

New Positive Data from Duvakitug Phase IIb TrialSources

Sanofi and Teva announced new positive data at week 44 of maintenance therapy in the Phase IIb trial of duvakitug, a drug in joint development, targeting ulcerative colitis and Crohn's disease.

New Release of ITP Treatment Drug "Weiriz® 400mg Tablets"Sources

Sanofi Co., Ltd. announced on October 21, 2026 the launch of the world’s first BTK inhibitor "Weiriz® 400mg tablets" for ITP.

Sarcircle® Receives Approval as a Dedicated DeviceSources

Sarcircle® has obtained approval as a dedicated device for the subcutaneous administration of Sarclisa®, a treatment for multiple myeloma.

Presentation of the Gap in Recognition Between Physicians and Patients in ITP CareSources

We presented the results of a survey on the recognition gap between physicians and patients in the treatment of immune thrombocytopenia (ITP) at the 88th Annual Meeting of the Japanese Society of Hematology (JSH).

Read the press releaseSources

Read the press release

New Release of Multiple Myeloma Treatment Drug 'Sarcisa® Subcutaneous 1400mg'Sources

Sanofi Inc. released the multiple myeloma treatment drug 'Sarcisa® Subcutaneous 1400mg' on August 27, 2026.

Considering the Future of Medicine from the Walls of Language and CultureSources

Sanofi held a special summer class on August 24, 2026, for students interested in the healthcare industry, exploring the future of medicine from the barriers of language and culture.

Read the press releaseSources

Read the press release

Withdrawal of amlitelimab approval applicationSources

Sanofi announced on July 30, 2026, that it has withdrawn the approval application for amlitelimab for atopic dermatitis from regulatory authorities worldwide.

§08

Public records

GOV
National Tax Agency basic information7011101037279
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
サノフィ株式会社
Trade name (kana)
サノフィ
Name in English
Corporation type
301
Address
〒160-0023 東京都新宿区西新宿3丁目20番2号
Postal code
1600023
Prefecture code
13
City code
104
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2024-08-27
Change date
2019-05-08
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
令和1年5月1日東京都中央区日本橋一丁目4番1号日本橋一丁目三井ビルディング14Fバイオベラティブ・ジャパン株式会社(7010001177978)を合併
Latest record
1
Excluded from search
0
Processing type
71
Correction type
1
Trade name image ID
Address image ID
Sequence number
2248271
METI gBizINFO7011101037279
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
7011101037279
Trade name
サノフィ株式会社
Trade name (kana)
サノフィ
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都新宿区西新宿3丁目20番2号
Postal code
1600023
Prefecture
東京都
Prefecture code
13
City or district
新宿区
City code
104
Street address
西新宿3丁目20番2号
Organisation type
301
Processing type
71
Correction type
1
Status
Representative
代表取締役 岩屋 孝彦
Capital
Employees
1430
Employees (male)
Employees (female)
Business summary
医薬品及び医療機器の製造販売・輸入、研究開発、医療機関への医薬品情報提供・収集ほか
Website URL
http://www.sanofi.co.jp
Year founded
Business category
E:製造業
Date established
1976-11-18
Unified government qualification - grade
|A||
Unified government qualification - business items
222
Update date
2024-08-27
Key information
7011101037279
§09

Sources & updates

SOURCES
↑